Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects.

Published

Journal Article

Genome-wide association studies (GWAS) for schizophrenia have identified over 100 loci encoding >500 genes. It is unclear whether any of these genes, other than dopamine receptor D2, are immediately relevant to antipsychotic effects or represent novel antipsychotic targets. We applied an in vivo molecular approach to this question by performing RNA sequencing of brain tissue from mice chronically treated with the antipsychotic haloperidol or vehicle. We observed significant enrichments of haloperidol-regulated genes in schizophrenia GWAS loci and in schizophrenia-associated biological pathways. Our findings provide empirical support for overlap between genetic variation underlying the pathophysiology of schizophrenia and the molecular effects of a prototypical antipsychotic.

Full Text

Duke Authors

Cited Authors

  • Kim, Y; Giusti-Rodriguez, P; Crowley, JJ; Bryois, J; Nonneman, RJ; Ryan, AK; Quackenbush, CR; Iglesias-Ussel, MD; Lee, PH; Sun, W; de Villena, FP-M; Sullivan, PF

Published Date

  • March 2018

Published In

Volume / Issue

  • 23 / 3

Start / End Page

  • 708 - 712

PubMed ID

  • 28555076

Pubmed Central ID

  • 28555076

Electronic International Standard Serial Number (EISSN)

  • 1476-5578

International Standard Serial Number (ISSN)

  • 1359-4184

Digital Object Identifier (DOI)

  • 10.1038/mp.2017.111

Language

  • eng